Insmed Incorporated Interest Expense 2011-2026 | INSM

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Insmed Incorporated

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
83.8 M	84.9 M	81.7 M	26.4 M	40.5 M	29.6 M	27.7 M	25.5 M	5.92 M	3.5 M	2.89 M	2.42 M	2.41 M	763 K	10 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
84.9 M	10 K	27.9 M

Quarterly Interest Expense Insmed Incorporated

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
21.2 M	21.6 M	-	21.1 M	21.3 M	21 M	-	20.3 M	20.6 M	20 M	-	3.35 M	3.36 M	3.29 M	-	11.2 M	10.3 M	7.56 M	-	7.18 M	7.47 M	7.41 M	-	6.85 M	6.78 M	6.73 M	-	6.68 M	6.49 M	5.64 M	-	1.5 M	1.49 M	1.47 M	-	769 K	624 K	622 K	-	725 K	718 K	722 K	-	594 K	595 K	606 K	-	525 K	635 K	643 K	-	222 K	1 K	2 K	-	2 K	3 K	4 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
21.6 M	1 K	6.36 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Assembly Biosciences ASMB	117 K	$ 28.46	3.45 %	$ 319 M	USA
Ascendis Pharma A/S ASND	80.6 M	$ 221.88	-0.87 %	$ 5 B	Danmark
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Axsome Therapeutics AXSM	-15.9 M	$ 156.92	-1.23 %	$ 7.81 B	USA
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Pharming Group N.V. PHAR	10 K	$ 15.36	-0.71 %	$ 7.59 B	Niderland
Autolus Therapeutics plc AUTL	9.29 M	$ 1.37	-4.2 %	$ 350 M	Britain
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Benitec Biopharma BNTC	-126 K	$ 10.98	-4.52 %	$ 452 M	USA
Inventiva S.A. IVA	12.2 M	$ 5.78	-4.3 %	$ 138 M	France
Compugen Ltd. CGEN	281 K	$ 2.09	-0.95 %	$ 195 M	Israel
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Foghorn Therapeutics FHTX	2.49 M	$ 5.0	2.25 %	$ 315 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.4	-3.68 %	$ 1.02 B	Canada
BioMarin Pharmaceutical BMRN	15.3 M	$ 54.13	-1.64 %	$ 10.4 B	USA
Curis CRIS	890 K	$ 0.77	1.89 %	$ 4.86 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	9 M	$ 1.52	-5.59 %	$ 178 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Cellectis S.A. CLLS	371 K	$ 3.34	-4.02 %	$ 116 M	France
Arbutus Biopharma Corporation ABUS	459 K	$ 4.24	-2.97 %	$ 704 M	Canada
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Cardiff Oncology CRDF	5 K	$ 1.8	-1.1 %	$ 120 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Iterum Therapeutics ITRM	-47 K	$ 0.16	-5.45 %	$ 3.15 M	Irlanda
Brickell Biotech BBI	5 K	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA